Results 211 to 220 of about 1,689,260 (355)

#3375 The alternative pathway of the renin angiotensin aldosterone system is overactivated in severe COVID-19 at baseline [PDF]

Irene Martínez Díaz, Jordi Vilardell, Sara Núñez-Delgado, Pablo Garcı́a de Frutos, Jose T. Ortiz‐Pérez, Antonio Cano Cámara, Carmen Llorens Cebrià, Albert Morales, Conxita Jacobs Cachá, María José Soler Romeo   +9 more
openalex   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Alternative Pathway for Methyl Supply through the Coupling of SHMT1 and PEMT to Maintain Astrocytic Homeostasis in Parkinson's Disease. [PDF]

Adv Sci (Weinh)
Chen YH, Zhu RX, Zhang NX, Sun TT, Zhang XW, Zhao YJ, He BY, Yao H, Du RH, Cao L, Zhang WB, Liu WG, Cai Y, Wang C, Hu G, Wei Y, Liu Y, Lu M.   +17 more
europepmc   +1 more source

Correction to: Mathematical Modelling of Alternative Pathway of Complement System. [PDF]

Bull Math Biol, 2021
Bakshi S, Cunningham F, Nichols EM, Biedzka-Sarek M, Neisen J, Petit-Frere S, Bessant C, Bansal L, Peletier LA, Zamuner S, van der Graaf PH.   +10 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Chronic kidney disease enhances alternative pathway activity: a new paradigm. [PDF]

J Clin Invest
Jalal DI, Thurman JM, Smith RJ.
europepmc   +1 more source

AAPM Task Group 298: Recommendations on certificate program/alternative pathway candidate education and training. [PDF]

J Appl Clin Med Phys, 2022
Prisciandaro JI, Burmeister JW, DeLuca PM, Gerbi BJ, Giger ML, Robar JL, Seibert JA.   +6 more
europepmc   +1 more source

Alternative pathways of dehydroascorbic acid degradation in vitro and in plant cell cultures: novel insights into vitamin C catabolism [PDF]

, 2011
Harriet T. Parsons, Tayyaba Yasmin, Stephen C. Fry   +2 more
openalex   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation. [PDF]

Front Nephrol
Heidenreich K, Goel D, Priyamvada PS, Kulkarni S, Chakurkar V, Khullar D, Singh R, Bale C, Zipfel PF.   +8 more
europepmc   +1 more source